AcquisitionOther
Fulgent Genetics, Inc. acquired Bako Diagnostics, a premier pathology laboratory,
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
Fulgent Genetics, Inc. -> Bako Diagnostics, a premier pathology laboratory, · $56.9 million
Fulgent’s therapeutic development business is focused on developing drug candidates for treating a broad range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of ne
Open source record (SEC) ↗